These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10448427)

  • 1. Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.
    Halliday GM; Pond SM; Cartwright H; McRitchie DA; Castagnoli N; Van der Schyf CJ
    Exp Neurol; 1999 Jul; 158(1):155-63. PubMed ID: 10448427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
    Patil R; Hiray Y; Shinde S; Langade P
    Pharm Biol; 2012 Jun; 50(6):691-7. PubMed ID: 22136413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study.
    Van der Schyf CJ; Dormehl IC; Oliver DW; Hugo N; Keeve R; Müller-Gärtner HW; Pond SM; Castagnoli N
    Brain Res Mol Brain Res; 1996 Dec; 43(1-2):251-8. PubMed ID: 9037540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridinium species in the baboon.
    Avent KM; Usuki E; Eyles DW; Keeve R; Van der Schyf CJ; Castagnoli N; Pond SM
    Life Sci; 1996; 59(17):1473-82. PubMed ID: 8890926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.
    Castagnoli N; Castagnoli KP; Van der Schyf CJ; Usuki E; Igarashi K; Steyn SJ; Riker RR
    Pol J Pharmacol; 1999; 51(1):31-8. PubMed ID: 10389142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tardive dyskinesia: an increased risk of neuroleptics in elderly women].
    Jessurun AY; Stek ML
    Tijdschr Gerontol Geriatr; 1995 Oct; 26(5):197-9. PubMed ID: 8750979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia.
    Eyles DW; Pond SM; Van der Schyf CJ; Halliday GM
    Life Sci; 2000 Feb; 66(14):1345-50. PubMed ID: 10755470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic medication facilitates the natural occurrence of tardive dyskinesia. A critical review.
    Driesens F
    Acta Psychiatr Belg; 1988; 88(3):195-205. PubMed ID: 2906780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)- 4-oxobutyl]-1,2,3,6-tetrahydropyridine (HPTP), an intermediate metabolite of haloperidol.
    Brand L; Oliver DW; van der Schyf CJ; Pond SM; Castagnoli N
    Life Sci; 1996; 59(10):815-20. PubMed ID: 8761315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia.
    Galili R; Mosberg ; Gil-Ad I; Weizman A; Melamed E; Offen D
    J Neural Transm (Vienna); 2000; 107(4):479-90. PubMed ID: 11215758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic defects caused by treatment with the tetrahydropyridine analog of haloperidol (HPTP), in baboons.
    Mienie LJ; Bergh JJ; Van Staden E; Steyn SJ; Pond SM; Castagnoli N; Van der Schyf CJ
    Life Sci; 1997; 61(3):265-72. PubMed ID: 9217286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.
    Van der Schyf CJ; Castagnoli K; Usuki E; Fouda HG; Rimoldi JM; Castagnoli N
    Chem Res Toxicol; 1994; 7(3):281-5. PubMed ID: 8075357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.